TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28373244
Drug: Intracoronary morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary morphine (3 mg of morphine sulfate diluted with 3 mL of normal saline)
Study: 28373244
Drug: Control (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (3 mL of normal saline)
Study: 28373244
Drug: Intracoronary morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary morphine
Study: 25149705
Drug: CoQ10 100
Normalized name: Walgreens CoQ10 100mg Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 100 mg per day (Q100)
Study: 25149705
Drug: CoQ10 300
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 300 mg per day (Q300)
Study: 21999406
Drug: Combined perianal-intrarectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined perianal-intrarectal lidocaine-prilocaine cream and lidocaine-ketorolac gel
Study: 21999406
Drug: Combined perianal-intrarectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined perianal-intrarectal lidocaine-prilocaine cream and periprostatic nerve block
Study: 9860085
Drug: Prednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (40 mg on day 1 decreased to 5 mg on day 7)
Study: 31331569
Drug: Massage with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage with topical 5 ml violet oil for 7 min during six sessions (two weeks)
Study: 28820681
Drug: Radiofrequency-induced heat
Normalized name: heather pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency-induced heat therapy (RFHT) at 50°C for 30 seconds
Study: 28820681
Drug: Intralesional sodium
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intralesional sodium stibogluconate (IL‐SSG) 1-3 mL given weekly until cure/10 doses
Study: 23167738
Drug: Sealed-capsule irrigation
Normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealed-capsule irrigation (SCI) using distilled water (DW) for 3 minutes
Study: 6112526
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg three times a day for 2 weeks
Study: 6112526
Drug: Metoclopramide 15
Normalized name: metoclopramide 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 15 mg three times a day for 2 weeks
Study: 6112526
Drug: Metoclopramide (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (any dose)
Study: 6112526
Drug: Metoclopramide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (5 mg)
Study: 19073791
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (7 mg/d as multivitamin preparation with ferrous sulfate)
Study: 19073791
Drug: Placebo (multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (multivitamin preparation without iron)
Study: 12414860
Drug: 7.5 IU
Normalized name: Follitropin Alfa 37.5 IU Subcutaneous Powder for Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 IU (2.5 mg) GH
Study: 7629641
Drug: i.v. tubing
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. tubing directly connected to the infusion device
Study: 17125466
Drug: Aspirin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (500 mg) + L-NMMA
Study: 17125466
Drug: Aspirin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (500 mg) + L-NMMA + Fluconazole (0.37 mg.min(‐1).l(‐1))
Study: 23660571
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3) 300 mg·kg‐1 body mass
Study: 23660571
Drug: Lactate (LACTATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate (LACTATE) 1115 mg
Study: 20056803
Drug: Sergliflozin etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sergliflozin etabonate (5-500 mg)
Study: 12570928
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17-beta estradiol (ERT)
Study: 12570928
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17-beta estradiol combined with continuous 5 mg medroxyprogesterone acetate (HRT)
Study: 10563646
Drug: Robot training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot training (MIT‐Manus) added to standard rehabilitation treatments
Study: 1702148
Drug: PVB (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVB (cisplatin 120 mg/m2 day 3, vinblastine 12 mg/m2 day 1, bleomycin 15 U/m2 twice per week)
Study: 1702148
Drug: VPV (vinblastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPV (vinblastine 8 mg/m2 day 1, cisplatin 120 mg/m2 day 3, VP‐16 50 mg/m2 days 2 to 5)
Study: 31301135
Drug: Vaccine-encoded adapted
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-encoded adapted epitopes
Study: 31301135
Drug: Higher HLA-I
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher HLA-I adaptation to the Gag vaccine insert
Study: 26194728
Drug: Suvorexant 40
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suvorexant 40 mg (multiple doses)
Study: 26194728
Drug: Suvorexant 40
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suvorexant 40 mg (single dose)
Study: 23158943
Drug: CPM combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPM combined with Tuina treatment
Study: 16308382
Drug: Animal facilitated
Normalized name: animals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal facilitated therapy with dolphins
Study: 11964641
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL lidocaine (Group A, n=60)
Study: 11964641
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL lidocaine combined with 1 mL triamcinolone (Group B, n=60)
Study: 7623251
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac rinse (0.1%) with placebo capsule
Study: 7623251
Drug: Systemic flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic flurbiprofen (50 mg bid) with placebo rinse
Study: 7623251
Drug: Placebo rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo rinse and capsule
Study: 2525351
Drug: Enoximone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 0.5 mg/kg i.v. as a bolus (30 s) before anesthesia
Study: 2525351
Drug: Enoximone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 0.5 mg/kg i.v. as a bolus (30 s) during anesthesia
Study: 2525351
Drug: Enoximone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 0.5 mg/kg i.v. as a bolus (30 s) during extracorporeal circulation (ECC)
Study: 2525351
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution as placebo (control group) before anesthesia
Study: 2525351
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution as placebo (control group) during anesthesia
Study: 2525351
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution as placebo (control group) during ECC
Study: 31013499
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment combined with conventional treatment (treatment group)
Study: 8607400
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment only (control group)
Study: 27676634
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg oral D2 agonist bromocriptine
Study: 27676634
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg oral haloperidol
Study: 24180001
Drug: Combination ART
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination ART and maraviroc
Study: 8856421
Drug: Imipramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine treatment (4 weeks duration)
Study: 1622639
Drug: FEC monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: FEC monthly (5-fluorouracil 500 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 500 mg/m2)
Study: 1622639
Drug: FEC weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: FEC weekly (5-fluorouracil 500 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 500 mg/m2)
Study: 1622639
Drug: FEC monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: FEC monthly
Study: 1622639
Drug: FEC weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: FEC weekly
Study: 25881576
Drug: Higher intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher intensity CRRT (40 mL/kg per hour)
Study: 25881576
Drug: Lower intensity
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower intensity CRRT (25 mL/kg per hour)
Study: 19900941
Drug: Single-dose cruciferous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose cruciferous diet
Study: 19900941
Drug: Double-dose cruciferous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose cruciferous diet
Study: 15566625
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (6 g per day containing 1.5 g DHA)
Study: 15566625
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 g per day of olive oil)
Study: 11678781
Drug: Artesunate 100
Normalized name: Artesunate 100 mg rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate 100 mg on days -5, 1, and 5; artemisinin 500 mg on days 1 and 5.
Study: 11678781
Drug: Artemisinin 500
Normalized name: ARTEMISININ
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin 500 mg on days -5, 1, and 5; artesunate 100 mg on days 1 and 5.
Study: 9577289
Drug: Ranitidine 0.5
Normalized name: ranitidine 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 0.5 mg/kg body weight twice a day for preterm infants
Study: 9577289
Drug: Ranitidine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 1.5 mg/kg body weight three times a day for term infants
Study: 3276111
Drug: Calcium heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin, 12,500 IU by the subcutaneous route
Study: 3276111
Drug: Placebo by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by the intramuscular route
Study: 26887879
Drug: Portable domestic
Normalized name: domestic cow dander extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Portable domestic pelvic floor neuromuscular electrical stimulation for 12 weeks after 4 weeks of hospital treatment
Study: 26887879
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor electrophysiological treatment in hospital for 4 weeks
Study: 19107187
Drug: Visual training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual training with six highly similar bird types; specific details on dosage and duration not available.
Study: 19107187
Drug: Visual training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual training with similar birds without established category-boundaries; specific details on dosage and duration not available.
Study: 15357562
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration (IV group, n = 25): ketamine 1 mg/kg and midazolam 0.05-0.1 mg/kg
Study: 15357562
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration (PO group, n = 24): ketamine 3 mg/kg and midazolam 0.5 mg/kg
Study: 15357562
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration (PR group, n = 24): ketamine 3 mg/kg and midazolam 0.5 mg/kg
Study: 1443450
Drug: terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 60 mg daily
Study: 1443450
Drug: terfenadine 120
Normalized name: terfenadine 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 120 mg daily
Study: 1443450
Drug: terfenadine 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 180 mg daily
Study: 1443450
Drug: terfenadine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine (all doses)
Study: 29090982
Drug: High-Dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose (HD) influenza vaccine (Fluzone® High-Dose)
Study: 29090982
Drug: Standard-Dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-Dose (SD) influenza vaccine (Fluzone®)
Study: 20042925
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and IV combined rehydration
Study: 20042925
Drug: All trials
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All trials (IV, oral, oral and IV combined, ad libitum)
Study: 18005804
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy for 45 minutes
Study: 10687110
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg once a day
Study: 8758156
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 0.5 mg
Study: 1837744
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with 1600 micrograms salbutamol or 160 micrograms ipratropium bromide daily
Study: 1837744
Drug: On demand
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On demand treatment with salbutamol or ipratropium bromide during exacerbations or periods of dyspnoea
Study: 7619569
Drug: On demand
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On demand treatment
Study: 6785100
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg/day for 3 days)
Study: 29218366
Drug: Haploidentical donor
Normalized name: Donor Human Stool
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haploidentical donor natural killer (NK) cell therapy with rituximab and IL‐2 (NK dose 0.5‐3.27 × 107 NK cells/kg)
Study: 29218366
Drug: Haploidentical donor
Normalized name: Donor Human Stool
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haploidentical donor natural killer (NK) cell therapy
Study: 23402476
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg) / Hydrochlorothiazide (HCTZ, 12.5 mg)
Study: 23402476
Drug: ARB +
Normalized name: revakinagene taroretcel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB + Calcium Channel Blocker (CCB)
Study: 17920723
Drug: Thalidomide 100mg
Normalized name: THALIDOMIDE 100MG CAP
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide 100mg orally daily with carboplatin and etoposide every 3 weeks for 6 cycles, followed by maintenance thalidomide for up to 2 years
Study: 7027891
Drug: Metoprolol 200
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 200 mg Durules once daily
Study: 7027891
Drug: Metoprolol 200
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 200 mg conventional tablets
Study: 17984409
Drug: Sustained-release bupropion
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release bupropion hydrochloride, 150 mg/d
Study: 17984409
Drug: Sustained-release bupropion
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release bupropion hydrochloride, 300 mg/d
Study: 7788825
Drug: Intranasal meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal meperidine (nasal group) - 27 mg per dose, self-administered, up to six puffs, with a minimum delay of 10 minutes between doses.
Study: 7788825
Drug: Subcutaneous meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous meperidine injections (sc group) - 25 or 50 mg on request.
Study: 2082312
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg and 90 mg
Study: 19178487
Drug: ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ingenol mebutate gel, 0.05%
Study: 19178487
Drug: vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle gel
Study: 8124991
Drug: Triazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.5 mg orally)
Study: 8124991
Drug: Meperidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (1 mg/kg, subcutaneously)
Study: 60570
Drug: Cotrimoxazole (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (4 tablets daily for 6-14 days)
Study: 60570
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antibacterial therapy)
Study: 31642726
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training program (10-minute program, 3 times weekly for 12 weeks) targeting quadriceps, hip abductor, and core muscle groups
Study: 29945625
Drug: GSH+L-citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSH+L-citrulline
Study: 29945625
Drug: L-citrulline-malate
Normalized name: citrulline malate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-citrulline-malate
Study: 24075613
Drug: PRGF-Endoret (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRGF-Endoret (3 injections on a weekly basis)
Study: 24075613
Drug: Durolane hyaluronic
Normalized name: hyaluronate Prefilled Syringe [Durolane]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durolane hyaluronic acid (1 single injection)
Study: 18243430
Drug: Mw vaccine
Normalized name: polyethyloxazoline (200000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mw vaccine (1st dose of 1x10(9) heat killed organisms, 2nd dose of 5x10(8) organisms after 6 months)
Study: 18243430
Drug: Mw vaccine
Normalized name: polyethyloxazoline (200000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mw vaccine
Study: 18243430
Drug: Mw vaccine
Normalized name: polyethyloxazoline (200000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mw vaccine with BCG scars
Study: 8952816
Drug: Intravenous linsidomine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous linsidomine 10 mg
Study: 8952816
Drug: Parenteral isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral isosorbide dinitrate
Study: 31473130
Drug: Oral TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TXA regimen
Study: 31473130
Drug: Combined topical/IV/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined topical/IV/oral TXA
Study: 29972742
Drug: Tecovirimat 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecovirimat 600 mg twice daily for 14 days
Study: 29972742
Drug: Tecovirimat 10
Normalized name: tecovirimat 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecovirimat 10 mg/kg for 14 days (monkeypox model)
Study: 29972742
Drug: Tecovirimat 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecovirimat 40 mg/kg for 14 days (rabbitpox model)
Study: 25609006
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus bevacizumab (cisplatin: 40 mg/m2, bevacizumab: 300 mg, every 2 weeks for 6 weeks)
Study: 25609006
Drug: Cisplatin only
Normalized name: Cisplatin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin only (control group, n=27, cisplatin: 40 mg/m2 every 2 weeks for 6 weeks)
Study: 21906813
Drug: Ahmed‐FP7 valve
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ahmed‐FP7 valve implant
Study: 21889801
Drug: Baerveldt‐350 implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baerveldt‐350 implant
Study: 17217210
Drug: Benzocaine 18%
Normalized name: BENZALKONIUM CL 0.2/BENZOCAINE 18% LIQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzocaine 18% gel
Study: 17217210
Drug: Lignocaine 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 5% ointment
Study: 14624816
Drug: 7% carbon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% carbon dioxide (CO2) gas inhalation
Study: 3627711
Drug: Infants over
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants over 1000 g birthweight in SC group
Study: 25406953
Drug: Topical insulin-like
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical insulin-like growth factor-1 (IGF-1) therapy
Study: 25406953
Drug: Intratympanic corticosteroid
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic corticosteroid therapy (Dexamethasone)
Study: 22716204
Drug: metformin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin (3 g daily)
Study: 18050189
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) plus intravenous methylprednisolone (IV MP)
Study: 16085528
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management (CM; payment for chewing at least 12 pieces/day on 10 of 15 intervention days, n = 34) plus standard treatment (ST) and brief feedback (BF)
Study: 16085528
Drug: Brief feedback
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief feedback (BF; n = 32) plus standard treatment (ST)
Study: 16085528
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (ST; n = 31)
Study: 12173710
Drug: Intravenous glutathione
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glutathione twice a day for 5 days
Study: 12173710
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution twice a day for 5 days
Study: 10226978
Drug: Theophylline (300-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (300-500 mg orally at night for 4-22 weeks)